347 related articles for article (PubMed ID: 30965283)
1. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
3. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.
Means C; Clayburgh DR; Maloney L; Sauer D; Taylor MH; Shindo ML; Coussens LM; Tsujikawa T
Head Neck; 2019 Aug; 41(8):2636-2646. PubMed ID: 30896061
[TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
8. Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma.
Lim J; Lee HS; Park J; Kim KS; Kim SK; Cho YW; Song YS
Endocrinol Metab (Seoul); 2023 Aug; 38(4):445-454. PubMed ID: 37461149
[TBL] [Abstract][Full Text] [Related]
9. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
11. AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Zheng L; Li S; Zheng X; Guo R; Qu W
Int Immunopharmacol; 2021 Jan; 90():107185. PubMed ID: 33218938
[TBL] [Abstract][Full Text] [Related]
12. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
13. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.
Yang Y; Xia S; Zhang L; Wang W; Chen L; Zhan W
Cancer Biol Ther; 2020 Jun; 21(6):522-532. PubMed ID: 32151175
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
[TBL] [Abstract][Full Text] [Related]
15. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
16. Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?
Villagelin DG; Santos RB; Romaldini JH
J Endocrinol Invest; 2011 Dec; 34(11):e403-8. PubMed ID: 21765238
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract][Full Text] [Related]
19. Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.
Nicolson NG; Brown TC; Korah R; Carling T
Surgery; 2020 Jan; 167(1):66-72. PubMed ID: 31439400
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
